Person:
Cheng, Hailing

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Cheng

First Name

Hailing

Name

Cheng, Hailing
Author's Publications: search.filters.isAuthorOfPublication.6e87a27f-09b3-4e2e-b455-c5e09130f178

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Publication
    Therapeutic Implications of GIPC1 Silencing in Cancer
    (Public Library of Science, 2010) Chittenden, Thomas W.; Pak, Jane; Rubio, Renee; Holton, Kristina; Prendergast, Niall; Glinskii, Vladimir; Schwede, Mathew; Howe, Eleanor A.; Aryee, Martin; Sultana, Razvan; Lanahan, Anthony A.; Holmes, Chris; Cheng, Hailing; Cai, Yi; Culhane, Aedin; Bentink, Stefan; Mar, Jessica Cara; Taylor, Jennifer; Hahn, William; Zhao, Jean; Iglehart, James; Quackenbush, John
    GIPC1 is a cytoplasmic scaffold protein that interacts with numerous receptor signaling complexes, and emerging evidence suggests that it plays a role in tumorigenesis. GIPC1 is highly expressed in a number of human malignancies, including breast, ovarian, gastric, and pancreatic cancers. Suppression of GIPC1 in human pancreatic cancer cells inhibits in vivo tumor growth in immunodeficient mice. To better understand GIPC1 function, we suppressed its expression in human breast and colorectal cancer cell lines and human mammary epithelial cells (HMECs) and assayed both gene expression and cellular phenotype. Suppression of GIPC1 promotes apoptosis in MCF-7, MDA-MD231, SKBR-3, SW480, and SW620 cells and impairs anchorage-independent colony formation of HMECs. These observations indicate GIPC1 plays an essential role in oncogenic transformation, and its expression is necessary for the survival of human breast and colorectal cancer cells. Additionally, a GIPC1 knock-down gene signature was used to interrogate publically available breast and ovarian cancer microarray datasets. This GIPC1 signature statistically correlates with a number of breast and ovarian cancer phenotypes and clinical outcomes, including patient survival. Taken together, these data indicate that GIPC1 inhibition may represent a new target for therapeutic development for the treatment of human cancers.